Alkindi Sprinkle

  • Corticosteroid-responsive disorders

Alkindi Sprinkle Generic Name & Formulations

General Description

Hydrocortisone 0.5mg, 1mg, 2mg, 5mg; oral granules in caps.

Pharmacological Class


How Supplied


Generic Availability


Alkindi Sprinkle Indications


Replacement therapy for adrenocortical insufficiency in pediatric patients.

Alkindi Sprinkle Dosage and Administration


Not established.


See full labeling. Individualize. Use lowest effective dose. Do not swallow caps. Do not chew or crush granules. Do not use in NG or gastric tubes. Open and hold the caps appropriately. Pour the granules directly onto tongue, onto a spoon and place in the mouth, or sprinkle onto a spoonful of cold/room temperature soft food (eg, yogurt or fruit puree); swallow within 5mins. Immediately follow with ingestion of fluids (eg, water, milk, breastmilk, formula). Initially 8–10mg/m2/day in 3 divided doses; may give twice daily in older pediatric patients. Switching from other oral hydrocortisone: use same total daily dose; monitor closely.

Alkindi Sprinkle Contraindications

Not Applicable

Alkindi Sprinkle Boxed Warnings

Not Applicable

Alkindi Sprinkle Warnings/Precautions


Adrenal crisis. Increase dose during periods of stress (eg, infections, gastroenteritis, surgery, or major trauma). Increased risk of new or exacerbation of latent infections with any pathogen (including viral, bacterial, fungal, protozoan or helminthic infections) with excessive doses. Monitor for adrenocortical insufficiency, infections, linear growth, weight gain, psychiatric reactions, visual disturbances. Monitor for Cushing’s syndrome every 6 months; may require more frequent monitoring in patients aged <1yr. Decrease in bone mineral density. Osteoporosis. May mask signs of GI perforation. Impending GI perforation, abscess, or other pyogenic infections. Diverticulitis. Fresh intestinal anastomoses. Peptic ulcer. Pregnancy. Nursing mothers.

Alkindi Sprinkle Pharmacokinetics


Hepatic (CYP3A4).


Half-life: 1.5 hours.

Alkindi Sprinkle Interactions


Potentiated by CYP3A4 inhibitors (eg, itraconazole, posaconazole, voriconazole, erythromycin, clarithromycin, ritonavir, grapefruit juice), cyclosporine (monitor). Antagonized by CYP3A4 inducers (eg, barbiturates, phenytoin, carbamazepine, oxcarbazepine, rifampin, rifabutin, efavirenz, nevirapine), estrogen/estrogen containing products. May potentiate cyclosporine (seizure risk). May antagonize anticoagulants (eg, warfarin); monitor. May need to adjust dose of antidiabetic agents. Increased risk of GI effects with aspirin, other NSAIDs; monitor. Caution with aspirin in hypoprothrombinemia.

Alkindi Sprinkle Adverse Reactions

Adverse Reactions

Fluid retention, alteration in glucose tolerance, elevated BP, behavioral and mood changes (monitor), increased appetite, weight gain; ophthalmic reactions (with prolonged use).

Alkindi Sprinkle Clinical Trials

See Literature

Alkindi Sprinkle Note

Not Applicable

Alkindi Sprinkle Patient Counseling

See Literature